MIST

Milestone Pharmaceuticals Inc.

1.54 USD
-0.07 (-4.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Milestone Pharmaceuticals Inc. stock is down -3.14% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 March’s closed higher than February. 100% of analysts rate it a buy.

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada.